S
Steven De Vleeschouwer
Researcher at Katholieke Universiteit Leuven
Publications - 102
Citations - 3287
Steven De Vleeschouwer is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Medicine & Glioma. The author has an hindex of 29, co-authored 70 publications receiving 2564 citations. Previous affiliations of Steven De Vleeschouwer include The Catholic University of America & Catholic University of Leuven.
Papers
More filters
Journal ArticleDOI
Gliomas: Diffusion Kurtosis MR Imaging in Grading
Sofie Van Cauter,Jelle Veraart,Jan Sijbers,Ronald R. Peeters,Uwe Himmelreich,Frederik De Keyzer,Stefaan Van Gool,Frank Van Calenbergh,Steven De Vleeschouwer,Wim Van Hecke,Stefan Sunaert +10 more
TL;DR: There were significant differences in kurtosis parameters between high-grade and low-grade gliomas; hence, better separation was achieved with these parameters than with conventional diffusion imaging parameters.
Journal ArticleDOI
Postoperative Adjuvant Dendritic Cell ^ Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme
Steven De Vleeschouwer,Steffen Fieuws,Stefan Rutkowski,Frank Van Calenbergh,Johannes van Loon,Jan Goffin,Raf Sciot,Guido Wilms,Philippe Demaerel,Monika Warmuth-Metz,Niels Soerensen,Johannes E. A. Wolff,Johannes E. A. Wolff,Sabine Wagner,Eckhart Kaempgen,Stefaan Van Gool +15 more
TL;DR: Adjuvant DC-based immunotherapy for patients with relapsed GBM is safe and can induce long-term survival and a trend to PFS improvement was shown in the faster vaccination schedule, which was observed in favor of the faster DC vaccination schedule with tumor lysate boosting.
Journal ArticleDOI
Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization.
Ana Rita Pombo Antunes,Isabelle Scheyltjens,Francesca Lodi,Julie Messiaen,Asier Antoranz,Johnny Duerinck,Daliya Kancheva,Liesbet Martens,Karen De Vlaminck,Hannah Van Hove,Signe Schmidt Kjølner Hansen,Francesca Maria Bosisio,Koen Van der Borght,Steven De Vleeschouwer,Steven De Vleeschouwer,Raf Sciot,Luc Bouwens,M. Verfaillie,Niels Vandamme,Roosmarijn E. Vandenbroucke,Olivier De Wever,Yvan Saeys,Martin Guilliams,Conny Gysemans,Bart Neyns,Frederik De Smet,Diether Lambrechts,Jo A. Van Ginderachter,Kiavash Movahedi +28 more
TL;DR: This article employed single-cell RNA sequencing and CITE-seq to map the glioblastoma immune landscape in mouse tumors and in patients with newly diagnosed disease or recurrence.
Journal ArticleDOI
Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.
Carolien Koks,Abhishek D. Garg,Michael Ehrhardt,Matteo Riva,Lien Vandenberk,Louis Boon,Steven De Vleeschouwer,Patrizia Agostinis,Norbert Graf,Stefaan W. Van Gool +9 more
TL;DR: The therapeutic activity of NDV against GL261 tumors, evidenced in an orthotopic mouse model, is described for the first time, and the importance of a functional adaptive immune system in this paradigm was demonstrated in immunodeficient Rag2−/− mice and in CD8+ T cell depleted animals, where NDV slightly prolonged survival, but failed to induce long‐term cure.
Journal ArticleDOI
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
Hilko Ardon,Stefaan Van Gool,Tina Verschuere,Wim Maes,Steffen Fieuws,Raf Sciot,Guido Wilms,Philippe Demaerel,Jan Goffin,Frank Van Calenbergh,Johan Menten,Paul Clement,Maria Debiec-Rychter,Steven De Vleeschouwer,Steven De Vleeschouwer +14 more
TL;DR: Full integration of autologous DC-based tumor vaccination into standard postoperative radiochemotherapy for newly diagnosed glioblastoma seems safe and possibly beneficial.